Abstract
Pharmaceutical industry funding has transformed much grassroots community activism on health into corporate-sponsored advocacy. This critical commentary outlines recent evidence about industry funding of patient advocacy groups, offers a commentary on the history of grassroots activism appearing in this issue of the journal, and calls for greater scrutiny of the impacts and ethics of such sponsorship.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Batt, S., J. Butler, O. Shannon, and A. Fugh-Berman. 2020. Pharmaceutical ethics and grassroots activism in the United States: A social history perspective. Journal of Bioethical Inquiry 17(1): https://doi.org/10.1007/s11673-019-09956-8.
Bero, L. 2018. Ten tips for spotting industry involvement in science policy. Tobacco Control 28(1): 1-2.
British Medical Journal. Too much medicine. https://www.bmj.com/too-much-medicine. Accessed February 5, 2020.
DeJong, C., T. Aguilar, C.W. Tseng, G.A. Lin, W.J. Boscardin, and R.A. Dudley. 2016. Pharmaceutical industry-sponsored meals and physician prescribing patterns for Medicare beneficiaries. JAMA Internal Medicine 176: 1114-1122.
Esfandiari, N., and K. Cotto. 2018. Addyi update. National Women’s Health Network, April 11. https://nwhn.org/addyi-update/. Accessed February 5, 2020.
Fabbri, A., S. Swandari, E. Lau, A. Vitry, and B. Mintzes. 2019. Pharmaceutical industry funding of health consumer groups in Australia: A cross-sectional analysis. International Journal of Health Services 49(2): 273-293.
Kopp, E., S. Lupkin, and E. Lucas. 2018. Patient Advocacy groups take in millions from drug makers. Is there a payback? Kaiser Health News, April 6. https://khn.org/news/patient-advocacy-groups-take-in-millions-from-drugmakers-is-there-a-payback/.
Lo, B., and M.J. Field. 2009. Conflict of interest in medical research, education, and practice. National Academies Press.
Lundh, A., J. Lexchin, B. Mintzes, J.B. Schroll, and L. Bero. 2017. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2: MR000033.pmid:28207928.
Moynihan, R. 2014. Evening the score on sex drugs: Feminist movement or marketing masquerade? BMJ 349: g6246.
Moynihan R., and L. Bero. 2017. Toward a healthier patient voice: More independence, less industry funding. JAMA Internal Medicine 177(3): 350-351.
Ozieranski, P., E. Rickartd, and S. Mulinari. 2019. Exposing drug industry funding of UK patient organisations. British Medical Journal 365: l1806.
Wang, A.T., C.P. McCoy, M.H. Murad, and V.M. Montori. 2010. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: Cross sectional systematicreview. British Medical Journal 340: c1344.
Wise, B., S. Obiorah, J. Kim, J. Eckert, S. Krensky, and A. Fugh-Berman. 2018. Fentanyl at your door: Who are pain groups advocating for? The Hastings Center Bioethics Forum, April 19. https://www.thehastingscenter.org/fentanyl-door-pain-groups-advocating/. Accessed February 5, 2020.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Moynihan, R. Commentary: The Voice of the People, Funded Now by Your Friendly Pharmaceutical Company. Bioethical Inquiry 17, 61–63 (2020). https://doi.org/10.1007/s11673-020-09965-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11673-020-09965-y